Patents Assigned to Changzhou Jiekai Pharmatech Co., Ltd.
  • Pyrazolo fused heterocyclic compounds as ERK inhibitors
    Patent number: 10696687
    Abstract: Disclosed herein is a compound of formula (I) and/or a pharmaceutically acceptable salt thereof that can serve as Erk inhibitors. They are potentially useful in the treatment of diseases treatable by inhibition of Erk, such as cancers. Also disclosed herein is a pharmaceutical composition, comprising a compound of formula I and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: June 30, 2020
    Assignee: Changzhou Jiekai Pharmatech Co., LTD.
    Inventors: Jintao Zhang, Wen Xu, Shanzhong Jian
  • Heterocyclic compounds as ERK inhibitors
    Patent number: 10479791
    Abstract: Disclosed herein is a compound of formula I and/or a pharmaceutically acceptable salt thereof that can serve as Erk inhibitors: They are potentially useful in the treatment of diseases treatable by inhibition of Erk, such as cancers. Also disclosed herein is a pharmaceutical composition comprising a compound of formula I and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: November 19, 2019
    Assignees: CHANGZHOU JIEKAI PHARMATECH CO. LTD, JS INNOPHARM (SHANGHAI) LTD
    Inventors: Jintao Zhang, Wen Xu, Shanzhong Jian
  • PYRAZOLO FUSED HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS
    Publication number: 20180237450
    Abstract: Disclosed herein is a compound of formula (I) and/or a pharmaceutically acceptable salt thereof that can serve as Erk inhibitors. They are potentially useful in the treatment of diseases treatable by inhibition of Erk, such as cancers. Also disclosed herein is a pharmaceutical composition, comprising a compound of formula I and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: August 20, 2015
    Publication date: August 23, 2018
    Applicant: CHANGZHOU JIEKAI PHARMATECH CO., LTD.
    Inventors: Jintao ZHANG, Wen XU, Shanzhong JIAN
  • HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS
    Publication number: 20180179211
    Abstract: Disclosed herein is a compound of formula I and/or a pharmaceutically acceptable salt thereof that can serve as Erk inhibitors: They are potentially useful in the treatment of diseases treatable by inhibition of Erk, such as cancers. Also disclosed herein is a pharmaceutical composition comprising a compound of formula I and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 3, 2015
    Publication date: June 28, 2018
    Applicants: CHANGZHOU JIEKAI PHARMATECH CO. LTD, JS INNOPHARM (SHANGHAI) LTD
    Inventors: Jintao ZHANG, Wen XU, Shanzhong JIAN
  • HETEROCYCLIC COMPOUNDS AS AXL INHIBITORS
    Publication number: 20170137426
    Abstract: Compounds of Formula I and their uses of effective AXL inhibitors and for the treatment of physical condition mediated by AXL.
    Type: Application
    Filed: March 28, 2014
    Publication date: May 18, 2017
    Applicant: Changzhou Jiekai Pharmatech Co., Ltd.
    Inventors: Jintao Zhang, Yibin Xiang, Wen Xu, Shnzhon Jian